Carlyle portfolio firms SeQuent Scientific and Viyash Life Sciences have got stock exchange approvals for their planned merger. The former is listed while the latter is not.
SeQuent Scientific conveyed the development in a stock exchange filing on Thursday.
As a next step, they will approach the national company law tribunal (NCLT) for approval.
Comments
Post a Comment